CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors

Cancer Immunology, Immunotherapy

Volumn 57, Issue 8, 2008, Pages 1151-1160

  Rakhmilevich, Alexander L ^a,c   Buhtoiarov, Ilia N ^a,c   Malkovsky, Miroslav ^b,c   Sondel, Paul M ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Anti CD40 mAb; Monocytes macrophages; T cells; Tumor Immunity

Indexed keywords

B16 HSP 72.1 VACCINE; CD40 ANTIGEN; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; GROWTH INHIBITION; IMMUNIZATION; IMMUNOGENICITY; IN VITRO SELECTION; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MACROPHAGE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LEUKEMIA L5178; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES;

EID: 44249125542     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0447-4     Document Type: Article

References (34)

1. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFA, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480
2. Buhtoiarov IN, Lum HD, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL (2005) CD40 ligation induces antitumor reactivity of murine macrophages via an IFN gamma-dependent mechanism. J Immunol 174:6013-6022
3. Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL (2006) Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 176:309-318
4. Campbell AC, Hersey P, MacLennan IC, Kay HE, Pike MC (1973) Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. BMJ 2:385-388
5. DeKruyff RH., Gieni RS, Umetsu DT (1997) Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J Immunol 158:359-366
6. Diehl L, Boer AT, Schoenberger SP, Voort E, Schumacher TNM, Melief CJM, Offringa R, Toes REM (1999) CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments antitumor vaccine efficacy. Nat Med 5:774-779
7. French RR, Chan HTC, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5:548-553
8. Gruber TA, Skelton DC, Kohn DB (2002) Requirement for NK cells in CD40 ligand-mediated rejection of Philadelphia chromosome-positive acute lymphoblastic leukemia cells. J Immunol 168:73-80
9. Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG, Agathanggelou A, Cullen N, Macartney J, Fanslow WC, Murphy WJ (1999) Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93:2999-3007
10. Hunig T (1983) T-cell function and specificity in athymic mice. Immunol Today 4:84-87
11. Imaizumi K, Kawabe T, Ichiyama S, Kikutani H, Yagita H, Shimokata K, Hasegawa Y (1999) Enhancement of tumoricidal activity of alveolar macrophages via CD40-CD40 ligand interaction. Am J Physiol 277: L49-L57
12. Kedl RM, Jordan M, Potter T, Kappler J, Marrack P, Dow S (2001) CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci USA 98:10811-10816
13. Leoprechting VA, Bruggen VDP, Pahl HL, Aruffo A, Simon JC (1999) Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59:1287-1294
14. Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL (2006) In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophages. J Leuk Biol 79:1181-1192
15. Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL (2006) Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumor-necrosis factor-α. Immunol 118:261-270
16. Mackey MF, Gunn JR, Ting P, Kikutani H, Dranoff G, Noelle RJ, Barth RJ (1997) Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 57:2569-2574
17. Nakajima A, Kodama T, Morimoto S, Azuma M, Takeda K, Oshima H, Yoshino S, Yagita H, Okumura K (1998) Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol 161:1901-1907
18. North RJ, Bursuker I. (1984) Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1 + 2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 159:1295-1311
19. O'Sullivan B, Thomas R (2003) CD40 and dendritic cell function. Crit Rev Immunol 23:83-107
20. Payer E, Strohal R, Kutil R, Elbe A, Stingl G (1992) Demonstration of a CD3+ lymphocyte subset in the epidermis of athymic nude mice. Evidence for T cell receptor diversity. J Immunol 149:413-420
21. + T-helper and a T-killer cell. Nature 393:474-478
22. Rolink A, Melchers F, Andersson J (1996) The SCID but not the RAG-2 gene product is required for 5 mu-S epsilon heavy chain class switching. Immunity 5:319-330
23. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483
24. Solomayer EF, Feuerer M, Bai L, Umansky V, Beckhove P, Meyberg GC, Bastert G, Schirrmacher V, Diel IJ (2003) Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res 9:174-180
25. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 5:780-787
26. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW (2004) Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 173:5923-5928
27. Todryk SM, Tutt AL, Green MH, Smallwood JA, Halanek N, Dalgleish AG, Glennie MJ (2001) CD40 ligation for immunotherapy of solid tumours. J Immunol Meth 248:139-147
28. Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, Yu H (2001) Anti-CD40 antibody induces antitumor and anti-metastatic effects: role of natural killer cells. J Immunol 166:89-94
29. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ (2002) T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 168:2720-2728
30. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE (2002) CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 99:5561-5566
31. Vesosky B, Hurwitz AA (2003) Modulation of costimulation to enhance tumor immunity. Cancer Immunol Immunother 52:663-669
32. Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B, Garl S, Butine MD, Perry VP, Armitage RJ, Ghalie R, Caron DA, Gribben JG (2001) Phase I study of recombinant human CD40 ligand in cancer patients. J Clinic Oncol 19:3280-3287
33. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clinic Oncol 25:876-883
34. Wells AD, Rai SK, Salvato MS, Band H, Malkovsky M (1998) Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 10:609-617